BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy

Yihang Chen 8/9/26 Yihang Chen 8/9/26

BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy

Read More

From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo?

Yihang Chen 7/26/26 Yihang Chen 7/26/26

From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo?

Read More

Clinical Going Global: Why Australia and Europe Matter More for Chinese Biotech

Yihang Chen 6/16/26 Yihang Chen 6/16/26

Clinical Going Global: Why Australia and Europe Matter More for Chinese Biotech

Read More

Candid Therapeutics and UCB: When China-Origin Assets Become Global Strategy

Yihang Chen 5/5/25 Yihang Chen 5/5/25

Candid Therapeutics and UCB: When China-Origin Assets Become Global Strategy

Read More